Hostname: page-component-7479d7b7d-k7p5g Total loading time: 0 Render date: 2024-07-09T00:43:53.731Z Has data issue: false hasContentIssue false
  • English
  • Français

Extrapyramidal side effects and functional remission in schizophrenia

Published online by Cambridge University Press:  23 March 2020

B. Ghajati ,
C. Leila ,
L. Raja  and
C. Majda
B. Ghajati
Affiliation:
Razi Hospital, Psychiatry Department “C”, Tunis, Tunisia
C. Leila
Affiliation:
Razi Hospital, Psychiatry Department “E”, Tunis, Tunisia
L. Raja
Affiliation:
Razi Hospital, Psychiatry Department “C”, Tunis, Tunisia
C. Majda
Affiliation:
Razi Hospital, Psychiatry Department “E”, Tunis, Tunisia

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Treating patients with schizophrenia has evolved towards including, as an effective goal, their functional remission. Beyond the discrepancies in this concept definition, a plethora of studies has been conducted trying to identify predictors of functioning in schizophrenia. Among which antipsychotic prescription and related side effects.

Aim

Explore extrapyramidal side effects link with functional prognosis of patients with schizophrenia spectrum disorder.

Methods

We conducted a cross-sectional, retrospective and descriptive study in the psychiatry department “C”, in Razi hospital (Tunis), between October 2014 and March 2015. Sixty patients suffering from schizophrenia spectrum disorder (DSM IV-R) were included. Functional status was explored with the Global Assessment of Functioning Scale (GAF), the Social and Occupational Functioning Assessment Scale (SOFAS) and the Social Autonomy Scale (EAS). Extrapyramidal side effects (EPS) were evaluated using the Simpson and Angus Rating Scale (SAS).

Results

Functional remission was achieved according to GAF, SOFAS and EAS in respectively: 63,30%, 48,30% and 51,70% of the patients. SAS mean score was 0.898 ± 0.29 (0.4–2). Although SAS showed no significant association with GAF, SOFAS and EAS global scores, patient with less EPS had better autonomy in EAS’ dimension “Relationship with the outside” (P = 0.048).

Conclusion

EPS may influence functional remission at several levels starting from the neurobiological to the social stigmatization and the treatment adherence levels. Further research in this matter is required.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster walk: Schizophrenia and other psychotic disorders–part 2
Information
European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. S195 - S196
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.